Free Trial
→ Warning: “DOGE Collapse” imminent (From Altimetry) (Ad)
NASDAQ:SCLX

Scilex 8/13/2024 Earnings Report

Scilex logo
$5.44 +0.34 (+6.67%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$5.50 +0.06 (+1.18%)
As of 05/2/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Scilex EPS Results

Actual EPS
-$6.30
Consensus EPS
-$7.00
Beat/Miss
Beat by +$0.70
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
$16.37 million
Expected Revenue
$13.17 million
Beat/Miss
Beat by +$3.20 million
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Date
8/13/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Scilex's next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Scilex Earnings Headlines

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
May 1 at 9:00 AM | globenewswire.com
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
April 30, 2025 | globenewswire.com
Trump Orders 'National Digital Asset Stockpile'
Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what could be the biggest wealth opportunity since Bitcoin's early days.
May 4, 2025 | Crypto 101 Media (Ad)
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
April 22, 2025 | globenewswire.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine
April 17, 2025 | marketwatch.com
Scilex treatment of pericarditis granted FDA orphan designation
April 17, 2025 | markets.businessinsider.com
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

View Scilex Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles